14:30 , Mar 19, 2019 |  BC Innovations  |  Distillery Therapeutics

ALK2 inhibition for diffuse intrinsic pontine glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Cell culture and mouse studies suggest inhibiting ALK2 could help treat diffuse intrinsic pontine glioma (DIPG) in patients harboring activating ALK2 mutations. In tumorspheres derived from an ALK2-mutant mouse...
17:41 , Jan 11, 2019 |  BC Week In Review  |  Financial News

Venture roundup: Apic, Stelexis, Biond, Keros

Gene therapy company Apic Bio Inc. (Cambridge, Mass.) and cancer company Stelexis Therapeutics LLC (New York, N.Y.) each announced series A rounds of at least $40 million. Other companies that announced venture rounds include Biond...
23:42 , Jan 8, 2019 |  BC Extra  |  Financial News

Venture roundup: Apic, Stelexis, Biond, Keros

Gene therapy company Apic Bio Inc. (Cambridge, Mass.) and cancer company Stelexis Therapeutics LLC (New York, N.Y.) each announced series A rounds this week of at least $40 million. Other companies that announced venture rounds...
22:55 , Oct 25, 2018 |  BC Innovations  |  Targets & Mechanisms

Blueprint for selectivity

Blueprint Medicines Corp. is making the jump from cancer to rare disease with an inhibitor for the rare pediatric bone disease FOP that sets the company up against at least two competitors further ahead in...
19:27 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Blueprint debuts selective ALK2 inhibitor for rare musculoskeletal disease

Blueprint Medicines Corp. (NASDAQ:BPMC) provided the first glimpse of its preclinical ALK2 inhibitor program, BLU-782, when it presented data at the American Society for Bone and Mineral Research (ASBMR) meeting in Montreal on Sept. 30....
15:30 , Sep 30, 2018 |  BC Extra  |  Preclinical News

Blueprint Medicines unveils preclinical data for rare bone disease program

Blueprint Medicines Corp. (NASDAQ:BPMC) provided the first glimpse of its preclinical ALK2 inhibitor program, BLU-782, when it presented data at the American Society for Bone and Mineral Research (ASBMR) meeting in Montreal on Sunday. Blueprint...
21:08 , Dec 30, 2016 |  BC Week In Review  |  Company News

Sumitomo, Tolero deal

Sumitomo will acquire Tolero for $200 million up front, up to $430 million in development milestones and up to $150 million in sales milestones. The deal will provide Sumitomo with alvocidib flavopiridol, which has completed...
08:00 , Nov 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Activin receptor-like kinase 2 (ALK2; ACVR1); activin A

Musculoskeletal disease INDICATION: Musculoskeletal Cell culture and mouse studies suggest antibodies against the ALK2 ligand activin A could help treat fibrodysplasia ossificans progressiva (FOP). In human cell-based assays, activin A induced signaling in a bone-formation...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Clinical News

THR-184: Completed Phase II enrollment

Thrasos completed enrollment of 452 patients in the double-blind, placebo-controlled, North American Phase II trial evaluating IV THR-184. Last year, an IDMC recommended that the study proceed with the high-dose arm and drop the 2...
01:34 , Apr 1, 2015 |  BC Extra  |  Financial News

Thrasos raises $21M in series D

Thrasos Therapeutics Inc. (Montreal, Quebec) raised $21 million in a series D round led by new investor BDC Capital and existing investor SR One. Current investors Advanced Technology Ventures; Fonds de solidarite FTQ; Lumira Capital;...